|
Basic Characteristics of Mutations
|
|
Mutation Site
|
G841A |
|
Mutation Site Sentence
|
Recombinant phenotyping of cytomegalovirus (CMV) pol region III mutations from clinical specimens showed that T813S and G841A each conferred foscarnet resistance and approximately threefold increased ganciclovir resistance; adding the UL97 mutation C592G increased ganciclovir resistance to approximately sixfold. |
|
Mutation Level
|
Amino acid level |
|
Mutation Type
|
Nonsynonymous substitution |
|
Gene/Protein/Region
|
Pol |
|
Standardized Encoding Gene
|
UL54
|
|
Genotype/Subtype
|
- |
|
Viral Reference
|
-
|
|
Functional Impact and Mechanisms
|
|
Disease
|
Cytomegalovirus infections
|
|
Immune
|
- |
|
Target Gene
|
-
|
|
Clinical and Epidemiological Correlations
|
|
Clinical Information
|
- |
|
Treatment
|
ganciclovir |
|
Location
|
- |
|
Literature Information
|
|
PMID
|
17709468
|
|
Title
|
Growth and drug resistance phenotypes resulting from cytomegalovirus DNA polymerase region III mutations observed in clinical specimens
|
|
Author
|
Chou S,Marousek GI,Van Wechel LC,Li S,Weinberg A
|
|
Journal
|
Antimicrobial agents and chemotherapy
|
|
Journal Info
|
2007 Nov;51(11):4160-2
|
|
Abstract
|
Recombinant phenotyping of cytomegalovirus (CMV) pol region III mutations from clinical specimens showed that T813S and G841A each conferred foscarnet resistance and approximately threefold increased ganciclovir resistance; adding the UL97 mutation C592G increased ganciclovir resistance to approximately sixfold. Bacterial artificial chromosome CMV clones containing pol mutation L845P were nonviable unless repaired with the wild-type sequence.
|
|
Sequence Data
|
-
|